Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- Congress lambastes FDA over risks related to diabetes drug
- WASHINGTON -- Safety concerns about a GlaxoSmithKline diabetes drug prompted some Democratic lawmakers on Wednesday to rebuke the Food and Drug Administration and call for increased regulation of the pharmaceutical industry. The controversy surrounding Glaxo's Avandia intensified when a medical expert told Congress that executives threatened to...
- Research articles 2007-06-07
- Glaxo, U.S. settle transfer pricing dispute.
- Byline: Audrey Nutt Feb 05, 2007 (Tax Notes International - ABIX via COMTEX) -- The US Internal Revenue Service IRS has reported details of a settlement with GlaxoSmithKline Glaxo. The $US3.4 billion settlement, announced on 11 September 2006, relates to a transfer pricing dispute...
- Research articles 2007-02-05
- IRS, Glaxo agree on big settlement
- WASHINGTON -- Drug giant GlaxoSmithKline agreed to pay $3.4 billion in the largest tax settlement in IRS history, resolving a dispute from the 1980s over the multinational company's U.S. profits. The disagreement concerned how much of the profits from certain drugs, particularly the ulcer and heartburn medication Zantac,...
- Research articles 2006-09-12
- Glaxo withdraws AIDS drug patent plan in Thailand, India
- BANGKOK AFP — British pharmaceutical firm GlaxoSmithKlein has dropped its controversial application to patent a key AIDS drug in Thailand and India, the company and international HIV campaigners have said. Glaxo, which introduced the drug Combid to Thailand four years ago, told AFP that it had informed the Thai...
- Research articles 2006-08-17
- Invitrogen's innovative solutions in the drug discovery continuum and Glaxo completes $1.4B purchase of flu vaccine maker.
- M2 PRESSWIRE-9 December 2005-US Financial Network: Invitrogen's innovative solutions in the drug discovery continuum and Glaxo completes $1.4B purchase of flu vaccine makerC1994-2005 M2 COMMUNICATIONS LTD RDATE:09122005 City of Industry, CA - Biotechnology industry news provided by Financial News USA...
- Research articles 2005-12-09
- EEOC claims Glaxo laid off Pennsylvania worker due to her pregnancy.
- By Linda Loyd, The Philadelphia Inquirer Knight Ridder/Tribune Business News Oct. 5--The U.S. Equal Employment Opportunity Commission alleged that GlaxoSmithKline P.L.C. improperly fired a temporary contract employee at its Conshohocken facility last year, three months after learning that the woman ...
- Research articles 2004-10-05
- Glaxo Dismisses Worries over Free-Trade Drug Deal.
- By Bill Condie, Evening Standard, London Knight Ridder/Tribune Business News Jun. 14--Drugs giant GlaxoSmithKline has dismissed as "fear-mongering" Australian concerns that a proposed free trade agreement with the US -- due to be debated in the Australian parliament this week --...
- Research articles 2004-06-14
- GlaxoSmithKline increases stake in US pharmaceutical firm
- LONDON AFP ? British pharmaceuticals giant GlaxoSmithKline has announced it is increasing its stake in privately-held US pharmaceutical company Theravance to 19 percent at a cost of more than one million dollars. Theravance was to receive 129 million dollars (193 million euros, 237 million dollars) -- "a significant part...
- Research articles 2004-03-31
- Glaxo Laid Low after US Stakes UKpound 2.7 Billion Tax Claim.
- Evening Standard, London Knight Ridder/Tribune Business News Jan. 13--Drugs giant GlaxoSmithKline has been landed with one of the biggest tax claims of all time after receiving a bill for more than $5 billion (UKpound 2.7 billion) from the US government. ...
- Research articles 2004-01-13
- Glaxo Pushes to Get Newly Approved Viagra Competitor in Stores.
- The Boston Globe Knight Ridder/Tribune Business News Aug. 22--Glaxo is racing to get its rival to Viagra on sale in America as early as next month after regulators gave the anti-impotence treatment the green light late on Tuesday. Levitra, a...
- Research articles 2003-08-22
- News: In brief - Glaxo strikes balance with shares and prices.
- The $131bn California Public Employees Retirement System CalPERS Board of administration has "commended" GlaxoSmithKline for cutting the price of its combination AIDS treatment drug, Combivir. Sean Harrigan, CalPERS president, said: "We asked the company to examine the price of their AIDS therapy drugs and...
- Research articles 2003-05-05
- California Pension Fund's Social, Corporate Activism Draws Attention.
- By Chris Gaither, The Boston Globe Knight Ridder/Tribune Business News Apr. 20--SACRAMENTO, Calif.--When the AIDS Healthcare Foundation wanted drug maker GlaxoSmithKline PLC to lower the $438 a person it charges in developing countries for a year's worth of AZT, it turned...
- Research articles 2003-04-20
- The Kansas City Star, Mo., Jerry Heaster Column.
- By Jerry Heaster, The Kansas City Star, Mo. Knight Ridder/Tribune Business News Mar. 16--BLAME CONGRESS, NOT GLAXO: The latest controversy over how best to provide affordable prescription drugs for seniors promises to hinder rather than help the cause. As...
- Research articles 2003-03-16
- Harvard Students Get Top Honors at Annual Marketing-Case Event at Wake Forest.
- By Kristi E. Swartz, Winston-Salem Journal, N.C. Knight Ridder/Tribune Business News Feb. 5--Bad weather and a delayed plane flight didn't stop a team of five Harvard University graduate-level business students from winning Wake Forest University's Babcock Graduate School of Management's annual marketing-case competition...
- Research articles 2002-02-05
- battle against drug-makers: An analysis of European union and United States merger enforement in the pharmaceutical industry 1995-1999, The
- The U.S. antitrust laws were written at a time when economic competition and markets were largely national. Today, the United States faces the need to enforce antitrust regulations in a world dominated by large, multinational companies, which compete in multiple geographic markets with the same products.1 As a result, there...
- Research articles 2001-01-01
- British pharma companies outline growth strategies
- Chief executives from Glaxo Wellcome, SmithKline Beecham, and Zeneca outlined their strategies for growth at the. 19th annual global healthcare conference in California sponsored by Goldman Sachs. Glaxo's Chief Executive Bob Ingram and Richard Kent, head of clinical trials, presented a positive outlook for the company based on five...
- Research articles 1998-08-01
- GATT Rx: profit overdose. (General Agreement on Tariffs and Trade)
- Pharmaceutical companies with name-brand products are expected to benefit from recent legislation changing the duration of US patents. At present, US patent holders can exclusively market their products for a period of 17 years from the time of a patent's issuance. Congress, in compliance with the GATT, has changed the...
- Research articles 1995-05-01
- Trading favors: while Congress debates trade policy, members quietly lift the barriers for their favorite importers - includes related articles - Cover Story
- While Congress debates trade policy, members quietly lift the barriers for their favorite importers. Dark-haired, tanned and dapper, Rep. Mel Levine (D-Calif.) took the House floor in July 1991 and condemned the Bush administration's trade policy with China. It would be "shameful," he said, if President Bush ignored the...
- Research articles 1993-03-22
- The big pill. (pharmaceutical industry)
- The pharmaceutical industry is under pressure from governments trying to keep the lid on health care costs because of the high price of its products. Those that do best in the decade ahead may have to adapt from the prevalent 'bigger is better' strategy. With drug companies under attack for...
- Research articles 1993-03-06
- Glaxo withdraws Lotronex under pressure
- > On the brink of a decision to take its controversial irritable bowel syndrome drug Lotronex direct-to-consumer as part of a unique risk-management plan, Glaxo Wellcome in December withdrew the product from the market under FDA pressure. After a tense, two-hour meeting with the agency in Washington on November 28,...
- Research articles 2001-01-01
- << Previous
- page 1 of 3
- Next >>
Content Types
Refining Tags
- GlaxoSmithKline Plc. (13 results)
- Finance (7 results)
- FDA (5 results)
- Government (5 results)
- Sales (4 results)
- Merck & Co. Inc. (4 results)
- U.S. Congress (4 results)
- Pharmaceutical Company (4 results)
- Biotechnology (4 results)
- H1N1 Flu (3 results)
- Internal Revenue Service (3 results)
- Strategy (3 results)
- Noven Pharmaceuticals Inc. (3 results)
- Pfizer Inc. (3 results)
- Healthcare (3 results)
- David P. Hamilton (3 results)
- Taxes (3 results)
- marketing (3 results)
- Vaccine (3 results)
